SPONSOR
Qilu Pharmaceutical Co., Ltd.
Total Trials
6
Recruiting
6
Phases
Phase 3, Phase 1, Phase 2
Conditions studied: Atopic DermatitisCancer CachexiaCancer Cachexia SyndromeEsophageal Squamous Cell Carcinoma (ESCC)Hospital-acquired Bacterial Pneumonia (HABP)Ventilator-associated Bacterial Pneumonia (VABP)Complicated Intra-abdominal Infection (cIAI)Complicated Urinary Tract Infection (cUTI)Bloodstream Infection (BSI)NSCLC
Qilu Pharmaceutical Co., Ltd. is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Atopic Dermatitis, Cancer Cachexia, Cancer Cachexia Syndrome, Esophageal Squamous Cell Carcinoma (ESCC).
The trial portfolio spans Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Qilu Pharmaceutical Co., Ltd.
How many clinical trials has Qilu Pharmaceutical Co., Ltd. sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by Qilu Pharmaceutical Co., Ltd., of which 6 are actively recruiting participants. These trials cover conditions including Atopic Dermatitis, Cancer Cachexia, Cancer Cachexia Syndrome. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Qilu Pharmaceutical Co., Ltd. research focus on?
Qilu Pharmaceutical Co., Ltd. clinical trials span Atopic Dermatitis, Cancer Cachexia, Cancer Cachexia Syndrome, Esophageal Squamous Cell Carcinoma (ESCC), Hospital-acquired Bacterial Pneumonia (HABP), and additional conditions. The research pipeline includes Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Qilu Pharmaceutical Co., Ltd. clinical trial?
To participate in a Qilu Pharmaceutical Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Qilu Pharmaceutical Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Qilu Pharmaceutical Co., Ltd.
NCT06880276 Phase 3
Recruiting
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
Atopic Dermatitis
NCT07735104 Phase 1, Phase 2
Recruiting
The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia
Cancer Cachexia
NCT07463573 Phase 3
Recruiting
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
NCT07089186 Phase 3
Recruiting
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Hospital-acquired Bacterial Pneumonia (HABP)
NCT06754644 Phase 3
Recruiting
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
NSCLC
NCT06383767 Phase 3
Recruiting
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Metastatic Breast Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology